A multicenter, phase II trial to investigate the safety and efficacy of Panitumumab and Irinotecan in Neo Ras Wild type metastatic colorectal cancer patients (C-PROWESS study)

未提供0 个研究点目标入组 30 人开始时间: 2022年6月17日最近更新: 2025年3月3日

试验速览

阶段: 不适用
状态: 进行中（未招募）
入组人数: 30
主要终点: -

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Single Arm Study
干预模型: Single Assignment
主要目的: Treatment Purpose
盲法: Open(masking Not Used)

入排标准

年龄范围: 20age old over 至 No limit（—）
性别: All

入选标准

•Patients eligible for inclusion in this study have to meet all of the following criteria:
•Must give written Informed Consent
•Histologically proven diagnosis of colorectal adenocarcinoma
•Advanced or recurrent colorectal cancer (excluding appendix and anal canal cancer)
•Age>= 20 years
•Eastern Cooperative Oncology Group (ECOG) performance status <= 2
•At least one measurable lesion according to RECIST version 1.1 criteria evaluated by CT or MRI within 28 days before registration
•RAS mutation (MT) (KRAS/NRAS exon 2, 3, or 4 MT) confirmed by tumor histology prior to the study enrollment
•Must have had documentation of the RAS WT confirmed within 28 days from test result date by ctDNA analysis using the OncoBEAM (TM) RAS CRC KIT
•Must have confirmed refractory or intolerant to previous treatments with chemotherapies including fluoropyrimidines, oxaliplatin, or irinotecan (irinotecan is applied to refractory only), regardless of prior treatment with trifluridine tipiracil hydrochloride, regorafenib, or angiogenesis inhibitors.
•Life expectancy of at least 60 days
•Adequate organ functions (bone marrow, liver, renal functions) as defined by the following laboratory values obtained within 14 days prior to the study enrollment:
•a.Absolute neutrophil count >= 1500/ mm3
•b.Platelets >= 75000/mm3
•c.Serum total bilirubin <= 1.5 mg/dL
•d.Serum AST(GOT) and ALT(GPT) <= 100 U/L(except for patients with tumor involvement of the liver who must have AST and ALT <= 200 U/L)
•e.Serum creatinine <= 1.5 mg/dL

排除标准

•Patients eligible for inclusion in this study must not meet any of the following criteria:
•Evidence of BRAF V600E MT by tumor histology.
•Treated with blood transfusion, blood products, or hematopoietic factor products such as Granulocyte Colony Stimulating Factor within 7 days prior to enrollment in this study.
•Have a history of severe drug hypersensitivity or severe drug allergy
•Active infection (fever of 38 degree or higher due to infection).
•Ascites, pleural effusion, or pericardial effusion requiring continuous drainage.
•Uncontrolled diabetes mellitus.
•Uncontrolled hypertension.
•Patients who have been treated with any of the following treatments prior to starting study drug:
•a.Extensive surgery <= 4 weeks prior to starting study drug (e.g., surgical treatment with organ resection, excluding colostomy)
•b.Proctocolectomy <= 2 weeks prior to starting study drug
•c.Any chemotherapy <= 2 weeks prior to starting study drug
•d.Radiotherapy <= 2 weeks prior to starting study drug
•Clinically significant electrocardiographic abnormality or clinically significant cardiovascular accidents within 6 months prior to study enrollment, including myocardial infarction, severe unstable angina, or New York Heart Association functional classification class III or IV congestive heart failure.
•Patients with severe lung disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema).
•History of clinically significant mental disorder or central nervous system disorder.
•Symptomatic brain metastasis or clinically suspected brain metastasis upon symptoms.
•Diarrhea that interferes with daily life.
•Intestinal paralysis, intestinal obstruction.
•Co-existing active malignancies.
•Pregnant or lactating women; women of childbearing potential or men with women partners of childbearing potential who are unwilling to use a highly effective method of contraception or avoid intercourse during and upon completion of the study. 17) Patients who are judged by the site physician to be inappropriate for this study.
•Patients who have been treated with EGFR inhibitors prior to starting study drug.

结局指标

主要结局

Response Rate

次要结局

未报告次要终点

研究者

发起方

未提供

相似试验

已完成

不适用

An observational study to follow clinical outcomes for the patients participated in the randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLOFX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancerColorectal Cancer

JPRN-UMIN000036690Department of Clinical Oncology, Kawasaki MEdical School JSWOG311

ACE study (ACE study)

jRCT103224050764

招募中

不适用

SCRUB study (SCRUB study)Bladder Tumor Bladder Cancer

jRCTs051230084110

进行中（未招募）

不适用

COMPASS study (COMPASS study)

jRCT1050240216AstraZeneca K.K.200